Transparency Market Research

Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Single User License: US $ 4595 Multi User License: US $ 7595 Corporate User License: US $ 10595
REPORT DESCRIPTION

Buy Now Request Sample

Published Date: Apr 2014

110 Pages Report

Antibacterial Drugs Market Expected to Reach USD 45.09 Billion Globally in 2019: Transparency Market Research According to a new market report published by Transparency and Market Research and

"Antibacterial Drugs Market (By Class- Aminoglycosides, -Lactams, Tetracyclines, Sulfonamides, Quinolones/Fluoroquinolones, Macrolides Phenicols, Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global antibacterial drugs market was valued at USD 43.55billion in 2012 and is expected to grow at a CAGR of0.3% from 2013 to 2019, to reach an estimated value of USD 45.09billion in 2019. Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html An antibacterial drug has been utilized by humans since the discovery of the first antibiotic penicillin in 1928 and has grown into a multi-billion dollar market since. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria, which cannot be treated by any other method unlike other diseases, where substitute

methodologies are available. This property has made antibacterial drugs an indispensable part of human healthcare. Antibacterial drugs are classified into seven major classes, namely, aminoglycosides, Lactams, tetracyclines, sulfonamides, quinolones, macrolides and phenicols. The -lactams class was the largest segment of the global antibacterial drugs market in 2012,with 57% share.Quinolones was identified as the second largest class, which held a share of 16.6% of the global antibacterial drugs market in 2012 and is expected to report a negative CAGR during the forecast period. This decline in revenue will be primarily witnessed due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones therapy.However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period. Factors such as increasing prevalence of infectious diseases and rising demand for effective as well as affordable antibacterial drugs especially from emerging economies of Asia-Pacific, Latin America, Middle East and Africa are the major growth drivers for the antibacterial drugs market. Globally, rise in elderly population is also being considered as one of the major growth factors as it will indirectly increase the demand for various antibacterial drugs. The demand for antibacterial drugs will continue to rise regardless of presence of a wide range of antibacterial drugs. This is mainly due to increased prevalenceof resistant species which demand development of innovative molecules. In 2012, Asia-Pacific held the largest share of the revenue generated by the global antibacterial drugs market. This region is also set to experience the highest growth rate during the forecast period 2013 to 2019. This is becausethe region accounts for the largest infected population in the world, by a variety of bacterial infections like pneumonia, tuberculosis, tetanus and others. Other factors includeincreasing multi-drug resistant bacterial strains, increasing availability of generic drugs and increasing purchasing power of the people of this region. India, one of the key markets in the Asia-Pacific region, isfamous for being the largest generic drug manufacturing nation. North America held the second largest revenue share, followed by Europe in the antibacterial drugs market in 2012.

At present, certain novel compounds are under investigation in both preclinical and clinical settings for the treatment of newly evolving drug-resistant bacterial species.Some of the major candidates such as Dalvance (Durata Therapeutics), tedizolidand surotomycin(Cubist Pharmaceuticals), and others are currently in phase III clinical trials. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, expected launch of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players operating in the global antibacterial drugs market. With very few patented products currently available in this market, the market is currently dominated by generic manufacturers to a great extent. With respect to the key revenue generating drugs (branded and generic) of this market, Pfizer, Inc. accounted for the largest market share in 2012, followed by Merck & Co., Inc. and GlaxoSmithKline plc. The global antibacterial drugs market is segmented as follows: Antibacterial Drugs Market, by Class Aminoglycosides -Lactams Tetracyclines Sulfonamides Quinolones/Fluoroquinolones Macrolides Phenicols

Antibacterial Drugs Market, by Geography North America Europe Asia-Pacific Rest of the World (RoW)

Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html TABLE OF CONTENTS Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Sources 1.3.1.1 Secondary Research 1.3.1.2 Primary Research

Chapter 2 Executive Summary Chapter 3 Market Overview 3.1 Introduction to Antibacterial Drugs 3.2 Market Trends and Future Outlook 3.2.1 Impact of generics 3.3 Market Drivers 3.3.1 Global increasing prevalence of a large number of infectious diseases

3.3.2 Rising demand for effective and affordable antibacterial drugs from emerging economies 3.3.3 Aging population 3.4 Market Restraints

Related & Recently Published Reports by Transparency Market Research Orthopedic Soft Tissue Repair Market: http://www.transparencymarketresearch.com/soft-tissue-repair-sports-medicine.html Nanocoatings Market: http://www.transparencymarketresearch.com/nanocoatingsmarket.html Calcium Carbonate Market: http://www.transparencymarketresearch.com/calciumcarbonate-market.html 3.4.1 Weak pipeline of novel antibacterial drugs 3.4.2 Patent expirations 3.4.3 Rising number of generic drugs in various antibacterial drug classes 3.4.4 Increasing number of multi-drug resistant bacterial strains 3.5 Market Opportunities 3.5.1 Product differentiation through technological innovation, use of monoclonal antibodies (mAbs), combination products, new formulations and indications 3.5.2 Product development through partnerships 3.6 Porters Five Forces Analysis for the Global Antibacterial Drugs Market 3.6.1 Bargaining power of suppliers 3.6.2 Bargaining power of buyers 3.6.3 Threat of substitutes 3.6.4 Threat of new entrants 3.6.5 Competitive rivalry 3.7 Market Attractiveness Analysis: Global Antibacterial Drugs Market, by Geography

Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)

4.1 Overview 4.1.1 Global Antibacterial Drugs Market Revenue, by Class, 2011 2019 (USD Million) 4.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Class, 2012 & 2019 (Value %) 4.2 Aminoglycosides 4.2.1 Global Aminoglycosides Market Revenue, 2011 2019 (USD Million) 4.3 B-Lactams 4.3.1 Global B-Lactams Market Revenue, 2011 2019 (USD Million) 4.3.2 Penicillins 4.3.3 Carbapenems 4.3.4 Cephalosporins 4.4 Tetracyclines 4.4.1 Global Tetracyclines Market Revenue, 2011 2019 (USD Million) 4.5 Sulfonamides 4.5.1 Global Sulfonamides Market Revenue, 2011 2019 (USD Million) 4.6 Quinolones/Fluoroquinolones 4.6.1 Global Quinolones/Fluoroquinolones Market Revenue, 2011 2019 (USD Million) 4.7 Macrolides

4.7.1 Global Macrolides Market Revenue, 2011 2019 (USD Million) 4.8 Phenicols 4.8.1 Global Phenicols Market Revenue, 2011 2019 (USD Million)

Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) 5.1 Overview 5.2 Delafloxacin (RX-3341) 5.2.1 Global Delafloxacin Market, 2015 2019 (USD Million) 5.3 Surotomycin (CB-315) 5.3.1 Global Surotomycin Market, 2016 2019 (USD Million) 5.4 Tedizolid (TR-701) 5.4.1 Global Tedizolid Market, 2015 2019 (USD Million) 5.5 Ceftolozane/Tazobactam 5.5.1 Global Ceftolozane/Tazobactam Market, 2015 2019 (USD Million) 5.6 Dalvance (dalbavancin) 5.6.1 Global Dalvance (dalbavancin) Market, 2015 2019 (USD Million) 5.7 Eravacycline (TP-434) 5.7.1 Global Eravacycline Market, 2016 2019 (USD Million) 5.8 Delamanid (OPC-67683) 5.8.1 Global Delamanid Market, 2017 2019 (USD Million) 5.9 CAZ AVI

Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

5.9.1 Global CAZ AVI Market, 2015 2019 (USD Million) 5.10 Solithromycin (CEM-101) 5.10.1 Global Solithromycin Market, 2016 2019 (USD Million) 5.11 MK-3415A 5.11.1 Global MK-3415A Market, 2016 2019 (USD Million) 5.12 Oritavancin 5.12.1 Global Oritavancin Market, 2015 2019 (USD Million)

Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) 6.1 Overview 6.1.1 Global Antibacterial Drugs Market Revenue, by Geography, 2011 2019 (USD Million) 6.1.2 Comparative Analysis: Global Antibacterial Drugs Market Revenue, by Geography, 2012 & 2019 (Value %) 6.2 North America 6.2.1 North America Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million) 6.3 Europe 6.3.1 Europe Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million) 6.4 Asia-Pacific

Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

6.4.1 Asia-Pacific Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million) 6.5 Rest of the World (RoW) 6.5.1 RoW Antibacterial Drugs Market Revenue, 2011 - 2019 (USD Million)

Chapter 7 Competitive Landscape 7.1 Market Share Analysis: Global Antibacterial Drugs Market (2012)

Chapter 8 Recommendations 8.1 Development of combination products 8.2 Generic pharmaceuticals: Targeting emerging markets such as India, China, Brazil, Mexico and South Africa 8.3 Strategic collaborations with small biotechnology and research companies

Chapter 9 Company Profiles 9.1 AstraZeneca plc 9.1.1 Company Overview 9.1.2 Financial Overview 9.1.3 Product Portfolio 9.1.4 Business Strategies 9.1.5 Recent Developments

9.2 Bayer AG 9.2.1 Company Overview 9.2.2 Financial Overview 9.2.3 Product Portfolio 9.2.4 Business Strategies 9.2.5 Recent Developments 9.3 Bristol-Myers Squibb Company 9.3.1 Company Overview 9.3.2 Financial Overview 9.3.3 Product Portfolio 9.3.4 Business Strategies 9.3.5 Recent Developments 9.4 Eli Lilly and Company 9.4.1 Company Overview 9.4.2 Financial Overview 9.4.3 Product Portfolio 9.4.4 Business Strategies 9.4.5 Recent Developments 9.5 Forest Laboratories, Inc. 9.5.1 Company Overview 9.5.2 Financial Overview

9.5.3 Product Portfolio 9.5.4 Business Strategies 9.5.5 Recent Developments 9.6 GlaxoSmithKline plc 9.6.1 Company Overview 9.6.2 Financial Overview 9.6.3 Product Portfolio 9.6.4 Business Strategies 9.6.5 Recent Developments 9.7 Johnson & Johnson 9.7.1 Company Overview 9.7.2 Financial Overview 9.7.3 Product Portfolio 9.7.4 Business Strategies 9.7.5 Recent Developments 9.8 Merck & Co., Inc. 9.8.1 Company Overview 9.8.2 Financial Overview 9.8.3 Product Portfolio 9.8.4 Business Strategies 9.8.5 Recent Developments

Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html

9.9 Novartis AG 9.9.1 Company Overview 9.9.2 Financial Overview 9.9.3 Product Portfolio 9.9.4 Business Strategies 9.9.5 Recent Developments 9.10 Pfizer, Inc. 9.10.1 Company Overview 9.10.2 Financial Overview 9.10.3 Product Portfolio 9.10.4 Business Strategies 9.10.5 Recent Developments 9.11 Sanofi 9.11.1 Company Overview 9.11.2 Financial Overview 9.11.3 Product Portfolio 9.11.4 Business Strategies 9.11.5 Recent Developments

About Us: Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse Global Antibacterial Drugs Market Report with Full TOC: http://www.transparencymarketresearch.com/antibacterial-drugs-market.html